» Articles » PMID: 17888131

Fear of Visual Loss in Patients with Diabetes: Results of the Prevalence of Diabetic Eye Disease in Tayside, Scotland (P-DETS) Study

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2007 Sep 25
PMID 17888131
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To describe the relationship between fear of visual loss and dependent variables (visual acuity, retinopathy treatment, severity of retinopathy) in community-based diabetic patients.

Methods: Subjects were identified from the Diabetes Audit and Research in Tayside, Scotland (DARTS) diabetes register. From a total of 4825 individuals known to have diabetes and who were resident in Dundee and Perth (population 216 204; diabetes prevalence 2.23%), 586 persons with diabetes were randomly selected. Participants completed a self-administered questionnaire in Likert grade format which incorporated two items addressing presence and intensity of fear of visual loss.

Results: Questionnaires were returned by 61.4% of the cohort. Fear of visual loss was 'often in mind' for 37% of respondents, and that fear was intense for 47.4%. Analysis by diabetes type revealed differences in reported fear of Type 1 and Type 2 patients in relation to disease and treatment variables. Linear regression highlighted the complexity of the issue with retinal status, acuity and treatment only partly explaining reported patient concern (r(2) range: 0.051-0.125 for presence of fear; 0.026-0.04 for intensity of fear, depending on diabetes type).

Conclusions: Fear of visual loss is preoccupying and intense for a substantial proportion of the diabetic population. Reasons for this are multiple and complex. Objective measures of visual impairment and retinal status are inadequate predictors of fear. Carers and researchers need to be mindful of this when approaching patients with diabetes.

Citing Articles

Changes in Visual Impairment due to Diabetic Retinopathy During 1980-2019 Based on Nationwide Register Data.

Purola P, Ojamo M, Gissler M, Uusitalo H Diabetes Care. 2022; 45(9):2020-2027.

PMID: 35838317 PMC: 9472510. DOI: 10.2337/dc21-2369.


What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient.

Strain W, Tsang C, Hurst M, McEwan P, Unadkat M, Meadowcroft S Diabetes Ther. 2020; 11(6):1381-1395.

PMID: 32424798 PMC: 7261289. DOI: 10.1007/s13300-020-00834-w.


Prediction models for development of retinopathy in people with type 2 diabetes: systematic review and external validation in a Dutch primary care setting.

van der Heijden A, Nijpels G, Badloe F, Lovejoy H, Peelen L, Feenstra T Diabetologia. 2020; 63(6):1110-1119.

PMID: 32246157 PMC: 7228897. DOI: 10.1007/s00125-020-05134-3.


Diabetic brain or retina? Visual psychophysical performance in diabetic patients in relation to GABA levels in occipital cortex.

Sanches M, Abuhaiba S, dAlmeida O, Quendera B, Gomes L, Moreno C Metab Brain Dis. 2017; 32(3):913-921.

PMID: 28361261 DOI: 10.1007/s11011-017-9986-3.


Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the retina of diabetic mice.

Ezquer M, Urzua C, Montecino S, Leal K, Conget P, Ezquer F Stem Cell Res Ther. 2016; 7:42.

PMID: 26983784 PMC: 4793534. DOI: 10.1186/s13287-016-0299-y.